Introduction {#S1}
============

*Pseudomonas aeruginosa (P. aeruginosa)* is an important opportunistic clinical pathogen, causing a variety of healthcare-associated infections, such as pneumonia, sepsis, wounds, and urinary tract infections \[[@R01], [@R02]\]. This organism is an important cause of septic mortality in burn patients \[[@R03]\]. *P. aeruginosa* is a major cause of chronic lung infections in children and young adults with cystic fibrosis and can be especially severe in neutropenic or cancer patients \[[@R04]\]. Infections caused by *P. aeruginosa* are often difficult to treat because of its intrinsic and acquired resistance to many commonly prescribed antimicrobial agents, eventually leading to the emergence of multidrug-resistant *P. aeruginosa* (MDRPA) strain \[[@R05]\]. *P. aeruginosa* is physiologically resistant to many antibacterial agents, especially to the extended- spectrum cephalosporins, due to the production of different classes of extended spectrum ß-lactamases (ESBLs), overproduction of chromosomal AmpC cephalosporinase, and non-enzymatic mechanisms, such as efflux pumps and outer membrane impermeability \[[@R06]\], among others. Nosocomial infections due to MDRPA strains are increasingly recognized throughout the world and are associated with increased morbidity, mortality, and cost of therapy \[[@R07], [@R08]\].

ESBLs are one of the main leading causes of resistance to ß-lactam antibiotics among Gram-negative bacteria \[[@R06]\]. These enzymes are plasmid-encoded β-lactamases that mediate resistance to penicillins, first-, second- and third- generation cephalosporins, such as cefotaxime, ceftriaxone, and ceftazidime \[[@R06], [@R09]\]. TEM, SHV, and CTX-M are the major genetic groups of ESBLs amongst clinically important Gram-negative bacteria \[[@R09], [@R10]\].

These enzymes are most commonly found in *Klebsiella pneumoniae (K. pneumoniae)* and *Escherichia coli (E. coli)* and are also observed in other clinical isolates of Enterobacteriaceae and *Pseudomonas* \[[@R11], [@R12]\]. The first TEM-type β-lactamase, produced by a clinical E. coli strain, was reported in 1965. The TEM-type ESBLs are derivatives of TEM-1 and TEM-2 \[[@R09]\]. The SHV-type ESBLs may be found in clinical isolates more frequently than any other types of ESBLs and have been reported from several countries in Europe, such as Austria, France, Italy, and Greece, as well as in the United States and Australia \[[@R06], [@R09], [@R10]\]. The CTX-M-type ESBLs developed from TEM and SHV and can be divided into five subgroups according to their amino acid sequence similarities, including CTX-M-I, CTX-M-II, CTX-M-III, CTX-M-IV, and CTX-M-V \[[@R13], [@R14]\]. Detection of ESBLs is important for the surveillance and epidemiological studies of their transmission in medical settings \[[@R15]\]. One major concern regarding the spread of ESBL-producing *P. aeruginosa* within hospital settings is the treatment failure to infections caused by this organism due to the limitations in therapeutic choices \[[@R09], [@R16]\]. There are few reports describing the prevalence of TEM- or SHVtype ESBLs in *P. aeruginosa* in Iran. The aims of this study were to determine the prevalence of ESBLs and to detect the *bla*~TEM~, *bla*~SHV~ and *bla*~CTX-M~-types ESBL genes among clinical isolates of P. aeruginosa collected from hospitals of Tehran and Qazvin, two central provinces of Iran.

Methods {#S2}
=======

Bacterial isolates {#S2a}
------------------

The clinical isolates of *P. aeruginosa* (one isolate per patient) were collected from hospitalized patients of Tehran and Qazvin provinces from March 2013 to December 2014. The bacterial isolates were collected from different clinical specimens, including urine, wounds, sputum, broncoalveolar lavage (BAL), trachea, and blood. These isolates were obtained from patients admitted to intensive care units (ICUs), internal medicine, general surgery, neurology, neurosurgery, and infectious disease wards. Specimens of these patients were sent to the microbiology laboratory of the hospitals under study. The study was approved by the ethics committee of Qazvin University of Medical Sciences (code IR.QUMS. REC.1394.147). Written informed consent was obtained from all subjects enrolled in this study. All isolates were identified as *P. aeruginosa* using standard microbiological and biochemical tests \[[@R17]\]. The isolates were stored at -70°C in trypticase soy broth (TSB) containing 20% glycerol and subcultured twice prior to testing.

ESBL screening {#S2b}
--------------

All isolates were initially screened for ESBLs production using the standard disc diffusion method, using ceftazidime (30μg), cefotaxime (30μg), ceftriaxone (30μg), cefpodoxim (30μg), and aztreonam (30μg). Isolates which were non-susceptible to any of third generation cephalosporins were selected for ESBLs detection phenotypically. The antibiotic disks were purchased from Mast (Mast Diagnostics Group Ltd). *P. aeruginosa* ATCC 27853 was used as a control strain in antimicrobial suscpetibility testings.

Confirmation of ESBL production {#S2c}
-------------------------------

Phenotypic confirmatory tests \[[@R18]\], which were designed for detecting ESBLs in *K. pneumoniae* and *E. coli*, were also performed by comparing the inhibition zone of disks containing cefotaxime or ceftazidime with and without clavulanic acid. *E. coli* ATCC 25922, *E. coli* ATCC 35218 and *K. pneumoniae* ATCC 700603 were used as the quality control strains in antimicrobial susceptibility testing.

Molecular detection of ESBL-encoding genes {#S2d}
------------------------------------------

ESBL-producing isolates were subjected to Polymerase Chain Reaction (PCR) targeting *bla*~TEM~, *bla*~SHV~, *bla*~CTXM-\ 1~, *bla*~CTX-M-2~, *bla*~CTX-M-8~, *bla*~CTX-M-9~, and *bla*~CTX-M-25~ genes using the specific primers listed in [Table I](#T1){ref-type="table"}. Plasmid DNA was extracted using plasmid mini extraction kit (Bioneer Company, Korea). The PCR amplifications were performed in a thermocycler (Applied Biosystems, USA) as follows: 96° C for 5 min and 35 cycles of 1 min at 96° C, 1 min at a specific temperature for each primer and 1 min at 72° C and a final extension step of 10 min at 72° C. Amplification reactions were prepared in a total volume of 25 μl (24 μl of PCR master mix plus 1 μl of template DNA) including 5 ng of genomic DNA, 2.0 U of Taq DNA polymerase, 10 mM dNTP mix at a final concentration of 0.2 mM, 50 mM MgCl~2~ at a final concentration of 1.5 mM, 1 μM of each primer, and 1X PCR buffer (final concentration). PCR products were electrophoresed on a 1% agarose gel at 100 volts and then were stained with ethidium bromide solution and finally visualized in gel documentation system (UVtec, UK). The purified PCR products were sequenced by the Macrogen Company (Seoul, Korea). The sequence alignment and bioinformatics analyses were performed using the Basic Local Alignment Search Tool (BLAST) online program of the National Center for Biotechnology Information (freely available at <http://blast.ncbi.nlm.nih.gov/Blast.cgi>).

###### 

Primers used in this study for detecting ESBL-encoding genes.

  -----------------------------------------------------------------------------------------
  Targets            Primer Sequences (5\'-3\')   Annealing Temperature (°C)   References
  ------------------ ---------------------------- ---------------------------- ------------
  TEM                ATGAGTATTCAACATTTCCG\        50                           19
                     GACAGTTACCAATGCTTAATCA                                    

  TEM (Sequencing)   TAACCATGAGTGATAACACT\        50                           19
                     CCGATCGTTGTCAGAAGTAA                                      

  SHV                CTTTACTCGCCTTTATCG\          50                           19
                     TCCCGCAGATAAATCACCA                                       

  SHV (Sequencing)   ACTGCCTTTTTGCGCCAGAT\        56                           19
                     CAGTTCCGTTTCCCAGCGGT                                      

  CTX-M-1 group      ATGGTTAAAAAATCACTGCGTC\      55                           20
                     TTGGTGACGATTTTAGCCGC                                      

  CTX-M-2 group      ATGATGACTCAGAGCATTCG\        55                           20
                     TGGGTTACGATTTTCGCCGC                                      

  CTX-M-8 group      ACTTCAGCCACACGGATTCA\        55                           20
                     CGAGTACGTCACGACGACTT                                      

  CTX-M-9 group      ATGGTGACAAAGAGAGTGCA\        55                           20
                     CCCTTCGGCGATGATTCTC                                       

  CTX-M-25           CACACGAATTGAATGTTCAG\        50                           21
                     TCACTCCACATGGTGAGT                                        
  -----------------------------------------------------------------------------------------

Statistical analysis was performed for descriptive statistics, including frequencies, cross-tabulation of microbiological, clinical, and demographic characteristics, using the commercial software Statistical analysis software package (version 16, IBM SPSS Corporation, Armonk, NY, USA).

Results {#S3}
=======

During the study period from March 2013 to December 2014, a total of 266 isolates of *P. aeruginosa* were collected from different clinical specimens including blood (94 isolates; 35.3%), urine (80 isolates; 30.1%), wounds (29 isolates; 10.9%), trachea (26 isolates; 9.8%), sputum (19 isolates; 7.1%), and BAL (18 isolates; 6.8%). Isolates were obtained from patients admitted to intensive care units (99-37.2%), internal medicine (64-24.1%), infectious diseases (61-22.9%), general surgery (26-9.8%), neurosurgery (12-4.5%), and neurology (4-1.5%) wards.

One hundred and twenty-five (47%) were male and 141 (53%) were female. Out of the 266 *P. aeroginosa* isolates, 262 (98.5%) isolates were non-susceptible to at least one of the antibiotics used in the screening test and, among these, 75 (28.6%) isolates were identified as potential ESBL producers using combined disk method. Fifty-nine (78.7%) of ESBL-producing isolates were found to be multidrug-resistant (MDR), i.e. showed intermediate or fully resistance to at least three different classes of antimicrobial agents including β-lactams, aminoglycosides, and fluoroquinolones. Amikacin (58.7%) and piperacillin-tazobactam (53.3%) showed the highest rates of susceptibility among antimicrobials tested in this study, respectively ([Table II](#T2){ref-type="table"}). Further, 41 (54.7%) and 40 (53.5%) ESBL-producing isolates were fully or intermediate resistant to meropenem and imipenem, respectively. ESBL-producing isolates were mainly recovered from urine (30.2%), followed by wound (28.3%) samples. The patients affected were mainly those admitted in ICU (54.7%) and the internal wards (45.1%), respectively ([Table III](#T3){ref-type="table"}). Of the 75 *P. aeruginosa* isolates with ESBL phenotype, *bla*~TEM-1~ (20-26.7%) was the most common gene, followed by *bla*~CTX-M-15~ (13- 17.3%), *bla*~SHV-1~ (5-6.7%), and *bla*~SHV-12~ (3-4%), either alone or in combination ([Table IV](#T4){ref-type="table"}). In this study, isolates were, instead, negative for *bla*~CTX-M-2~, *bla*~CTX-M-8~, and *bla*~CTX-M-9~- group genes, as well as for *bla*~CTX-M-25~.

###### 

Antimicrobial susceptibility of ESBL-producing P. aeruginosa isolated from hospitals of Qazvin and Tehran (n = 75).

  Antibiotics               S (%)       I (%)       R (%)
  ------------------------- ----------- ----------- -----------
  Amikacin                  44 (58.7)   10 (13.3)   21 (28)
  Piperacillin-tazobactam   40 (53.3)   9 (12)      26 (34.7)
  Imipenem                  35 (46.7)   9 (12)      31 (41.3)
  Meropenem                 34 (45.3)   7 (9.3)     34 (45.3)
  Cefepime                  30 (40)     1 (1.3)     44 (58.7)
  Piperacillin              26 (34.7)   8 (10.7)    41 (54.7)
  Ciprofloxacin             24 (32)     1 (1.3)     50 (66.7)
  Gentamicin                22 (29.3)   \-          53 (70.7)
  Ceftazidime               22 (29.3)   4 (5.3)     49 (65.3)
  Tobramycin                22 (29.3)   3 (4)       50 (66.7)
  Ofloxacine                21 (28)     2 (2.7)     52 (69.3)
  Levofloxacin              18 (24)     2 (2.7)     55 (73.3)
  Ticarcillin               17 (22.7)   1 (1.3)     57 (76)
  Aztreonam                 14 (18.7)   10 (13.3)   51 (68)
  Carbenicilin              14 (18.7)   3 (4)       58 (77.3)
  Ceftriaxone               10 (13.3)   7 (9.3)     58 (77.3)
  Cefotaxime                5 (6.7)     8 (10.7)    62 (82.7)

S: Sensitive, I: Intermediate, R: Resistant.

###### 

Frequency of ESBL-producing isolates broken down by hospitals ward and source of clinical specimen.

  Hospital wards       n (%)
  -------------------- -----------
  ICU                  33 (44)
  Internal medicine    19 (25.3)
  Infectious disease   12 (16)
  Surgery              8 (10.7)
  Neurosurgery         2 (2.7)
  Neurology            1 (1.3)
  Clinical specimens   (n/%)
  Blood                24 (32)
  Urine                17 (22.7)
  Trachea              13 (17.3)
  Wound                9 (12)
  BAL                  6 (8)
  Sputum               6 (8)

ICU: intensive care unit, BAL: bronchoalveolar lavage

###### 

Distribution of *bla*~SHV~,*bla*~TEM~, and *bla*~CTX-M~ genes in ESBL-producing *P. aeruginosa* isolates.

  Resistance genes                        n (%)
  --------------------------------------- -----------
  blaSHV-1                                4 (5.3)
  blaSHV-12                               3 (4)
  blaTEM-1                                12 (16)
  blaCTX-M-15                             4 (5.3)
  blaSHV-1 and blaCTX-M-15                1 (1.3)
  blaTEM-1 and blaCTX-M15                 8 (10.7)
  No blaTEM-1, blaSHV-1 and blaCTX-M-15   43 (57.3)

Discussion {#S4}
==========

*P. aeruginosa* has recently emerged as a major cause of healthcare-associated infections, especially in immunocompromised people and burn patients \[[@R22], [@R23]\]. The treatment of *P. aeruginosa* infections is increasingly complicated due to both intrinsic and acquired resistance to the most commonly prescribed antibiotics in hospital settings \[[@R02], [@R24]\]. The emergence of ESBL has become a matter of serious concern for the treatment of patients in Iran. ESBL detection is not routinely tested in most laboratories in Iran. There are only few reports on prevalence of ESBL among *P. aeruginosa* isolates in our country.

In the present study, 262 (98.5%) *P. aeruginosa* isolates were non-susceptible to at least one of the antibiotics used in the ESBL screening test and, among these, 75 (28.6%) isolates were ESBL positive. The prevalence rate of ESBL in our study is lower than the rate reported by Mirsalehian et al. (39.4%) \[[@R25]\] and Shakibaie et al. (34%) \[[@R26]\] from two burn centers in Iran, Begum et al. from Bangladesh (37.8%) \[[@R27]\], and Senthamaria et al. from India (42.3%) \[[@R28]\], but higher than the rate found by Zafar et al. from Egypt (7.4%) \[[@R29]\], Umadevi et al. from India (19.4%) \[[@R30]\] and Woodford et al. from United Kingdom (3.7%) \[[@R31]\]. In our study, 78.7% of ESBLproducing isolates were found to be MDR and showed relatively higher resistance rates to most antibiotics tested. These results are in accordance with those of other studies, such as those conducted by Fallah et al. and Hakemi Vala et al. in Iran \[[@R32], [@R33]\]. Our findings demonstrated that amikacin (58.7%) and piperacillin-tazobactam (53.3%) showed the highest rates of susceptibility among the antimicrobials tested, whereas cefotaxime and ceftriaxone revealed low suscepibility rates of 6.7% and 13.3%, respectively. The inappropriate management of infections through unnecessary and widespread administration of antibacterial agents is likely to be the main predisposing factor leading to the emergence of resistant bacteria in our medical centers. Moreover, the high resistance rate of ESBLs found among the isolates in this study emphasizes the need for a local and national antimicrobial resistance surveillance system for monitoring the administration of antimicrobials in our hospital settings.

It should be noted that, in this study, 71.5% of extended spectrum cephalosporin non-susceptible isolates were ESBL negative, which can be associated with other resistance mechanisms such as overproduction of chromosomal cephalosporinase (AmpC), up-regulation of efflux systems or decreased outer-membrane permeability. Additionally, our data showed that 54.7% and 53.5% of ESBL-producing isolates were non-susceptible to meropenem and imipenem, respectively. Since in hospital setting the appropriate treatment of infections caused by MDR Gram-negative bacteria is generally achieved by the administration of carbapenems, this finding indicated that the available therapeutic choices are currently limited. This has a relevant clinical impact, especially in the future in case these strains should become more prevalent. This study, in line with previous studies \[[@R34], [@R35]\], showed that ESBL-producing isolates were mostly collected from the patients admitted to ICUs. It seems that prolonged period of ICU stay, exposure to broad spectrum antibiotics, chronic underlying conditions, and the use of invasive techniques and devices predispose patients to infection caused by these resistant isolates.

In the present study, 26.7%, 17.3%, 6.7%, and 4% of ESBL-producing *P. aeruginosa* isolates carried *bla*~TEM-1~, *bla*~CTX-M-15~, *bla*~SHV-1~, and *bla*~SHV-12~ genes alone or in combination, respectively. In the literature, there have been only rare reports of *bla*~SHV-12~ and *bla*~CTX-M-15~-types ESBLs among *P. aeruginosa* worldwide. We believe that this is the first report of *bla*~CTX-M-15~ and *bla*~SHV-12~-related ESBL genes among *P. aeruginosa* isolates collected from Qazvin and Tehran hospitals. Shakibaie et al. reported that 6.6%, 4.1%, and 2.5% of ESBL-producing *P. aeruginosa* isolates carried *bla*~SHV~, *bla*~PER~, and *bla*~TEM~ family genes, respectively \[[@R26]\]. In another study from Iran, Shahcheraghi et al. reported that 24%, 22%, 17%, and 9% of MDR isolates of *P. aeruginosa* harbored *bla*~VEB~, *bla*~SHV~, *bla*~PER~, and *bla*~TEM~ genes, respectively \[[@R36]\]. In Japan, Uemura et al. showed the presence of *bla*~SHV-12~ among *P. aeruginosa* isolates collected from burn patients \[[@R37]\]. Polotto et al. reported that the *bla*~CTX-M-2~ (19.6%) gene was the most prevalent ESBL gene in Brazil \[[@R38]\]. Together, these data indicate successful spread of the ESBL-encoding genes around the world.

Conclusions {#S5}
===========

Findings of the our study show a high prevalence of ESBL- producing *P. aeruginosa* isolates carrying *bla*~CTX-M-15~ and *bla*~SHV-12~ genes in Iran. The presence of ESBL-producing bacteria within the healthcare setting in Iran should be considered a public health concern both therapeutically and epidemiologically. As such, the identification, treatment, and infection control and management of patients infected with these organisms is of prime necessity.
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